The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
 
Frederick L. Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Celgene; Cellular Biomedicine Group; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Novartis; Sana Biotechnology; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Justin Chou
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Five Prime Therapeutics; Gilead Sciences
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Saran Vardhanabhuti
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
Research Funding - Kite, a Gilead Company
 
Regis Perbost
Employment - HalioDx
 
Peter Dreger
Honoraria - Gilead Sciences; Novartis
Consulting or Advisory Role - Gilead Sciences; Novartis
Speakers' Bureau - Gilead Sciences; Novartis
 
Brian T Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Catherine Lee
Honoraria - Bristol-Myers Squibb; CareDX; Jazz Pharmaceuticals; Kadmon; Kite, a Gilead Company
Consulting or Advisory Role - Fresenius Kabi; Incyte; Jazz Pharmaceuticals
Research Funding - Incyte
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Nicolaus Kroeger
Honoraria - AOP Orphan Pharmaceuticals; Celgene (Inst); Jazz Pharmaceuticals (Inst); Kite/Gilead; Novartis; RIEMSER (Inst); Sanofi
Consulting or Advisory Role - Celgene; Gilead Sciences; Jazz Pharmaceuticals; Neovii; Novartis; RIEMSER; Sanofi
Speakers' Bureau - AOP Orphan Pharmaceuticals
Research Funding - Celgene (Inst); Neovii (Inst); Novartis (Inst); Riemser (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Jazz Pharmaceuticals; Neovii; Novartis; Sanofi
 
Armando López-Guillermo
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Incyte; Kite, a Gilead Company; Roche; Takeda
Research Funding - Celgene; Gilead Sciences; Incyte; Roche
 
Hildegard Greinix
Consulting or Advisory Role - Amgen; Gilead Sciences; Kite, a Gilead Company; Miltenyi Biotec; Novartis; Sanofi; Takeda; Therakos
Speakers' Bureau - Celgene; Jazz Pharmaceuticals; Novartis; Takeda; Therakos
 
Wangshu Zhang
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Gayatri Tiwari
Employment - Kite, a Gilead Company
 
Christina Ann To
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Paul C. Cheng
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Adrian Bot
Employment - Capstan Therapeutics; Kite, a Gilead Company
Stock and Other Ownership Interests - Cero Therapeutics; Elicio Therapeutics; Kite, a Gilead Company
Consulting or Advisory Role - Cero Therapeutics; Elicio Therapeutics
 
Rhine Shen
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite/Gilead
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics
 
Simone Filosto
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
Patents, Royalties, Other Intellectual Property - Tusk Therapeutics
 
Jerome Galon
Employment - Veracyte
Leadership - HalioDx
Stock and Other Ownership Interests - Veracyte
Consulting or Advisory Role - Catalym; IO Biotech; Lunaphore Technologies; Northwest Biotherapeutics
Research Funding - Akoya Biosciences (Inst); AstraZeneca (Inst); ImCheck therapeutics (Inst); NanoString Technologies (Inst); Ultivue (Inst)
Patents, Royalties, Other Intellectual Property - INSERM (French NIH)
Travel, Accommodations, Expenses - Veracyte